Clinical Report: Focused Ultrasound Stimulation for Schizophrenia
Overview
Transcranial focused ultrasound stimulation (tFUS) shows potential in targeting deep brain regions for schizophrenia treatment. Early studies indicate feasibility and tolerability; however, evidence for efficacy remains limited.
Background
Schizophrenia affects approximately 1% of the global population and is characterized by disruptions in brain connectivity. Current treatments, primarily pharmacological, do not adequately address the dysfunction in specific neural circuits for all patients, as noted in recent guidelines. This has led to interest in non-invasive neuromodulation techniques like tFUS, which may offer a more targeted approach.
Data Highlights
No numerical data available in the source material.
Key Findings
tFUS has been shown to reverse cognitive deficits and prevent psychotic-like behaviors in rodent models, as reported in preclinical studies.
In patients, tFUS targeting the dorsolateral prefrontal cortex has been associated with reductions in negative symptoms, according to early clinical trials.
Reported targets for tFUS include the dorsolateral prefrontal cortex, globus pallidus, and striatal circuits, based on current research.
Challenges include small sample sizes, short follow-up periods, and issues with blinding due to auditory confounds, as highlighted in the literature.
Future studies should adopt standardized reporting frameworks and rigorous sham procedures, as recommended by the ITRUSST consensus.
Clinical Implications
Current evidence is insufficient to support definitive clinical recommendations regarding tFUS for treating schizophrenia.
Conclusion
Current evidence is insufficient to support definitive conclusions about the therapeutic potential of tFUS in schizophrenia.
Genetically predicted urinary metabolite levels were associated with schizophrenia, bipolar disorder, attention-deficit/hyperactivity disorder, and anorexia nervosa in a Mendelian randomization analysis.
